ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT03897543
- Phase
- Phase 1, Phase 2
Drug identity checked against registry records
Also recorded as Obefazimod
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaNCT03897543 | ABVX | Phase 1, Phase 2 | Completed | 2022-04-14Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |